Rani Therapeutics Holdings, Inc.
corporate_fare Company Profile
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for RANI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for RANI spans 8-K, 10-Q, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- Rani Wins 180-Day Nasdaq Extension to May 10, 2027, Moves to Nasdaq Capital Market
- Rani Q3 Loss Widens to $8.8M; $45.3M Cash Funds Operations Through 2027
- Nasdaq Delisting Deadline and Unremediated Material Weakness Weigh on Rani Therapeutics
- Rani Therapeutics Q2 2026: RT-114 Expansion Cohort Dosed, Cash Runway Through 2027
- Rani's Oral Obesity Drug RT-114 Beats Injectable on Bioavailability in Phase 1a
Financial Snapshot
Short Interest & Short Volume
17.20 days to coverFINRA reported short interest of 8,219,380 shares in RANI as of the October 30, 2026 settlement, a 0.8% increase from the prior period — about 17.2 days to cover at its recent average daily volume. On November 19, 2026, 70.3% of RANI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for RANI, detected from its recent SEC filings · based on capital-structure filings through 2026-05-27.
Capital Raise Finalized · Pricing at Premium
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →